Related Experiment Video

Updated: Jun 19, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation

John C Araujo1, Ann Poblenz, Paul Corn

  • 1Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. johna@mdanderson.org

Cancer Biology & Therapy
|October 27, 2009
PubMed
Abstract

Insights

Dasatinib effectively inhibits osteoclast formation and activity, crucial for prostate cancer bone metastases. This Src kinase inhibitor shows promise as a targeted therapy for bone tumors.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Prostate cancer bone metastases have limited treatment options.
  • Targeting the interaction between cancer cells, bone cells, and the bone matrix is a key research area.
  • Osteoclasts are critical in the development of bone tumors associated with prostate cancer.

Purpose of the Study:

  • To investigate the efficacy of dasatinib, a Src family kinase inhibitor, in reducing osteoclast activity.
  • To determine if dasatinib can inhibit prostate cancer (PC-3) cell-induced osteoclast formation.
  • To evaluate dasatinib as a potential therapy for prostate cancer bone metastases.

Main Methods:

  • In vitro experiments were conducted using dasatinib, a Src family kinase inhibitor.
  • Osteoclast differentiation and activity were assessed.
  • Experiments utilized mouse primary bone marrow-derived monocytes and the murine monocytic cell line RAW 264.7, along with the human prostate cancer cell line PC-3.

Main Results:

  • Dasatinib inhibited RANKL-induced osteoclast differentiation with an EC50 of 7.5 nM.
  • Dasatinib suppressed PC-3 cell-induced osteoclast differentiation of RAW 264.7 cells.
  • Dasatinib inhibited osteoclast activity, measured by collagen 1 release, by 58%.

Conclusions:

  • Dasatinib effectively inhibits osteoclast differentiation and activity.
  • Targeting osteoclast differentiation and activity with dasatinib may offer an effective therapeutic strategy for prostate cancer bone metastases.
  • Further research into dasatinib as a targeted therapy for bone metastases is warranted.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...